-
BioCardia
$BCDA Rating Lowered to Sell at Zacks Investment Research http://tickerreport.com/?p=5002725 -
Biotech coverage (NYSE: ATNM) Announces collaboration w/UC Davis and a potential cure for HIV - https://mailchi.mp/broadstreetalerts/we-believe-this-will-be-another-potential-triple-digit-gainer-90569?e=[UNIQID …]
#biotech,#biotechstocks,$CTXR,$TTNP,$DARE,$ACST,$ADAP,$AMRN,$VBIV,$MREO,$BCDA,$VRNA,$BCDA,$CFRX,$ENLV,$BTAI,$ARDS,$NSTG,$OBSV,$GILD,$AMGN -
Made $811.50 on 2 shorts. Mainly on
$BCDA $650. Thanks Tim@timothysykespic.twitter.com/UHLQiXrksV
-
-
$BCDA BioCardia Receives FDA 510k Approval For 8F Morph DNA Deflectable Guide Catheter https://pro.benzinga.com/?afmc=5s#daytrade#daytrading#stocks#stockmarketnews#stockstowatch#referrallink -
One I never heard of
$BCDA ??Ongoing BCDA-01 Phase 3 trial heart failure based on promising Phase 2 data ─ In a Phase 2 trial BCDA-01 met primary safety endpoint with no treatment emergent major adverse cardiac events (MACE) at 30 days. pic.twitter.com/pOTWM36QBt
-
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
HOT